GLUTATHIONE ADVOCACY UPDATE
Dear Patients and Prescribers,
Your comments matter! More than 8,000 public comments in favor of compounded glutathione were heard and counted!
A huge thank you to everyone who advocated for the importance of glutathione access through compounding pharmacies like Lee Silsby.
Yesterday, June 8, 2022, FDA’s Pharmacy Compounding Advisory Committee (PCAC) ruled in favor of glutathione's inclusion on the 503a's bulk drug list and rejected FDA’s argument that all compounded glutathione should be banned in the United States. 8 out of 14 committee members voted YES to compounded glutathione.
The Lee Silsby Compounding Pharmacy team is proud to advocate alongside you and support your needs with high-quality compounded glutathione drugs.
Thank you! Our work is important because of you!
To review all public comments regarding the PCAC meeting, go to: https://www.regulations.gov/document/FDA-2021-N-0357-2586